Tiny stem cell companies close in on major heart disease goals

Athersys scientists review cell count data for the company's experimental Multistem treatment on Dec 12, 2017.
Athersys scientists review cell count data for the company's experimental Multistem treatment on Dec 12, 2017.PHOTO: REUTERS
Published
1 hour ago